Combined Regimens in Immunotherapy


Authors: B. Melichar;  M. Spisarová
Authors‘ workplace: Onkologická klinika LF UP a FN Olomouc
Published in: Klin Onkol 2017; 30(Supplementum3): 45-49
Category: Review
doi: 10.14735/amko20173S45

Overview

The advent of immunotherapy has changed our concept of how to manage metastatic disease. With the exception of relatively rare tumors, the treatment of metastatic cancer is still considered as palliative, and in systemic treatment immunotherapy is often selected, considering better tolerance. Immunotherapy opens the perspective of a long-term, possibly durable, response, and, in contrast to other approaches to targeted therapy, is active across a spectrum of tumors. Combined regimens that increase the efficacy, given the context, are thus of importance. The most promising results are currently obtained using a combination of ipilimumab and nivolumab for the treatment of metastatic malignant melanoma and metastatic renal cell carcinoma. Toxicity of the treatment can be managed by supportive care, and combination immunotherapy is gradually becoming established as a standard option in the management of these two neoplastic disorders. Moreover, additional trials using a combination of ipilimumab and nivolumab to treat other tumors are underway as well as studies of other combinations, including those that employ antibodies acting on immune checkpoints in combination with other targeted agents or cytotoxic chemotherapy. Other options include combinations with surgical therapy, i.e., adjuvant or neoadjuvant administration of immunotherapy or with radiotherapy based on the abscopal effect of radiation. Thus, although the results of combination immunotherapy are very promising, this strategy is still in its infancy. Thus, only the next generation of clinical trials will be able to determine to what extent these combined regimens can meet the high expectations of medical oncologists and the general public.

Key words:
immunotherapy – ipilimumab – nivolumab – pembrolizumab The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
27. 9. 2017

Accepted:
3. 10. 2017


Sources

1. Kirkwood JM, Butterfield LH, Tarhnini AA. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012; 62 (5): 309–335. doi: 10.3322/caac.20132.

2. Hodi FS, O Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–723. doi: 10.1056/NEJMoa1003466.

3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372 (26): 2521–2532. doi: 10.1056/NEJMoa1503 093.

4. Hodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17 (11): 1558–1568. doi: 10.1016/S1470-2045 (16) 30366-7.

5. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373 (1): 23–34. doi: 10.1056/NEJMoa1504030.

6. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377 (14): 1345–1356. doi: 10.1056/NEJMoa1709684.

7. Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372 (21): 2006–2017. doi: 10.1056/NEJMoa1414428.

8. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 2011; 364 (26): 2517–2526. doi: 10.1056/NEJMoa1104621.

9. Antonia SJ, Lopez-Martin JA, Bendell J et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17 (7): 883–895. doi: 10.1016/S1470-2045 (16) 30098-5.

10. Hellmann MD, Rizvi NA, Goldman JW et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017; 18 (1): 31–41. doi: 10.1016/S1470-2045 (16) 30 624-6.

11. Ham mers HJ, Plimack ER, Infante JR et al. Safety and Ef ficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol 2017; 35 (34): 3851–3858. doi: 10.1200/JCO.2016.72.1985.

12. Escudier B, Tannir NM, McDermott DF et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann Oncol 2017; 28 (Suppl 5): 605–649. doi: 10.1093/annonc/mdx 440.

13. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56 (18): 4264–4266.

14. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2 (10): 1096–1103.

15. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370 (9605): 2103–2111. doi: 10.1016/S0140-6736 (07) 61904-7.

16. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28 (13): 2144–2150. doi: 10.1200/JCO.2009.26.7849.

17. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010; 28 (13): 2137–2143. doi: 10.1200/JCO.2009.26.5561.

18. Negrier S, Gravis G, Perol D et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12 (7): 673–680. doi: 10.1016/S1470-2045 (11) 70124-3.

19. Melichar B, Bracarda S, Matveev V et al. A multinational phase II trial of bevacizumab with low-dose interferon-alfa2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol 2013; 24 (9): 2396–2402. doi: 10.1093/annonc/mdt228.

20. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19 (8): 1470–1476. doi: 10.1093/annonc/mdn161.

21. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007; 25 (12): 1539–1544. doi: 10.1200/JCO.2006.09.6305.

22. Hurwitz H, Febrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335–2342. doi: 10.1056/NEJMoa032691.

23. Lang I, Brodowicz T, Ryvo L et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14 (2): 125–133. doi: 10.1016/S1470-2045 (12) 70 566-1.

24. Zhang W, Gordon M, Schultheis AM et al. ECGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25 (24): 3712–3718. doi: 10.1200/JCO.2006.08.8021.

25. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26 (11): 1789–1796. doi: 10.1200/JCO.2007.14.8 957.

26. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2-and interferon-2alfa-based immunochemotherapy in advanced renal cell carcinoma: A prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22 (7): 1188–1194. doi: 10.1200/JCO.2004.06.155.

27. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338 (18): 1272–1278. doi: 10.1056/NEJM199804303381805.

28. Eton O, Legha S, Bedikian A et al. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha2b (INF) versus CVD in patients (pts) with metastatic melanoma. Proc ASCO 2000; 19: 552a.

29. Melichar B, Studentová H, Kalabova H et al. Predictive and prognostic significance of tumor-infitrating lymphocytes in patients with breast cancer treated with neodjuvant systemic therapy. Anticancer Res 2014; 34 (3): 1115–1125.

30. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016; 375 (19): 1823–1833. doi: 10.1056/NEJMoa1606774.

31. Carbone DP, Reck M, Paz-Ares L et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017; 376 (25): 2415–2426. doi: 10.1056/NEJMoa1613493.

32. Langer CJ, Gadgeel SM, Borghaei H et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17 (11): 1497–1508. doi: 10.1016/S1470-2045 (16) 30498-3.

33. Govindan R, Szczesna A, Ahn MJ et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Smal l-Cell Lung Cancer.J Clin Oncol 2017; 35 (30): 3449–3457. doi: 10.1200/JCO.2016.71.7629.

34. Eggermont AMM, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16 (5): 522–530. doi: 10.1016/S1470-2045 (15) 70122-1.

35. Weber J, Mandala M, Del Vecchio M et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377 (19): 1824–1835. doi: 10.1056/NEJMoa1709030.

36. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366 (10): 925–931. doi: 10.1056/NEJMoa1112824.

37. Antonia SJ, Vil legas A, Daniel D et al. Durvalumab after Chemoradiother apy in Stage III Non-Smal l-Cell Lung Cancer. N Engl J Med 2017; 377 (20): 1919–1929. doi: 10.1056/ NEJMoa1709937.

Labels
Paediatric clinical oncology Surgery Clinical oncology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

×